{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:17:27Z","timestamp":1790306247084,"version":"4.1.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose of Review<\/jats:title>\n            <jats:p>The use of statins has transformed approaches to the prevention of cardiovascular disease. However, many patients remain at a major risk of experiencing cardiovascular events, due to a range of factors including suboptimal control of low-density lipoprotein cholesterol (LDL-C). Accordingly, there is an ongoing need to develop additional strategies, beyond the use of statins, to achieve more effective reductions in cardiovascular risk.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent Findings<\/jats:title>\n            <jats:p>Genomic studies have implicated the causal role of LDL in atherosclerosis and identified that polymorphisms influencing factors involved in lipid metabolism influence both the level of LDL-C and cardiovascular risk. These findings have highlighted the potential for cardiovascular benefit from development of therapies targeting these factors and incremental benefit when used in combination with statins. Clinical trials have demonstrated that these new agents have favourable effects on both atherosclerotic plaque and cardiovascular events. Additional work has sought to improve intensification of statin therapy and adherence with lipid lowering therapy, to achieve more effective cardiovascular prevention via lipid lowering.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Emerging therapies, beyond statins, have the potential to optimise lipid levels and play an effective role in the prevention of cardiovascular disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11883-025-01280-4","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T10:29:02Z","timestamp":1739615342000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Achieving More Optimal Lipid Control with Non-Statin Lipid Lowering Therapy"],"prefix":"10.1007","volume":"27","author":[{"given":"Stephen J.","family":"Nicholls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"24","key":"1280_CR1","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Boren","year":"2020","unstructured":"Boren J, Chapman MJ, Krauss RM, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41(24):2313\u201330.","journal-title":"Eur Heart J"},{"issue":"32","key":"1280_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"9753","key":"1280_CR3","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"13","key":"1280_CR4","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","volume":"285","author":"GG Schwartz","year":"2001","unstructured":"Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711\u20138.","journal-title":"JAMA"},{"issue":"15","key":"1280_CR5","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"8934","key":"1280_CR6","first-page":"1383","volume":"344","author":"Randomised trial of cholesterol lowering","year":"1994","unstructured":"Randomised trial of cholesterol lowering. In 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S). Lancet. 1994;344(8934):1383\u20139.","journal-title":"Lancet"},{"issue":"15","key":"1280_CR7","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"1280_CR8","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"issue":"12","key":"1280_CR9","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","volume":"35","author":"P Amarenco","year":"2004","unstructured":"Amarenco P, Labreuche J, Lavallee P, Touboul PJ. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke. 2004;35(12):2902\u20139.","journal-title":"Stroke"},{"issue":"9256","key":"1280_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0140-6736(00)04053-8","volume":"357","author":"TJ Smilde","year":"2001","unstructured":"Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577\u201381.","journal-title":"Lancet"},{"issue":"16","key":"1280_CR11","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","volume":"106","author":"AJ Taylor","year":"2002","unstructured":"Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN. ARBITER: arterial Biology for the investigation of the Treatment effects of reducing cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation. 2002;106(16):2055\u201360.","journal-title":"Circulation"},{"issue":"6A","key":"1280_CR12","doi-asserted-by":"publisher","first-page":"M5","DOI":"10.1016\/S0002-9149(98)00591-8","volume":"82","author":"CM Ballantyne","year":"1998","unstructured":"Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol. 1998;82(6A):M5\u201311.","journal-title":"Am J Cardiol"},{"issue":"19","key":"1280_CR13","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1161\/CIRCULATIONAHA.108.773747","volume":"117","author":"CM Ballantyne","year":"2008","unstructured":"Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458\u201366.","journal-title":"Circulation"},{"issue":"9","key":"1280_CR14","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071\u201380.","journal-title":"JAMA"},{"issue":"13","key":"1280_CR15","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365.","journal-title":"JAMA"},{"issue":"22","key":"1280_CR16","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387.","journal-title":"N Engl J Med"},{"issue":"9","key":"1280_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1161\/01.CIR.0000140261.58966.A4","volume":"110","author":"S Okazaki","year":"2004","unstructured":"Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation. 2004;110(9):1061\u20138.","journal-title":"Circulation"},{"issue":"4","key":"1280_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jacc.2009.04.033","volume":"54","author":"T Hiro","year":"2009","unstructured":"Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol. 2009;54(4):293\u2013302.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1280_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.atherosclerosis.2015.06.007","volume":"241","author":"S Auscher","year":"2015","unstructured":"Auscher S, Heinsen L, Nieman K, et al. Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography. Atherosclerosis. 2015;241(2):579\u201387.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1280_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jcmg.2016.04.013","volume":"10","author":"S Shin","year":"2017","unstructured":"Shin S, Park HB, Chang HJ, et al. Impact of intensive LDL cholesterol lowering on coronary artery atherosclerosis progression: a serial CT Angiography Study. JACC Cardiovasc Imaging. 2017;10(4):437\u201346.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"1280_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2013.08.019","volume":"231","author":"I Zeb","year":"2013","unstructured":"Zeb I, Li D, Nasir K, et al. Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study. Atherosclerosis. 2013;231(2):198\u2013204.","journal-title":"Atherosclerosis"},{"issue":"4","key":"1280_CR22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ehjci\/jet251","volume":"15","author":"R Puri","year":"2014","unstructured":"Puri R, Libby P, Nissen SE, et al. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014;15(4):380\u20138.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"1280_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.4244\/EIJV12I6A118","volume":"12","author":"RM Oemrawsingh","year":"2016","unstructured":"Oemrawsingh RM, Garcia-Garcia HM, van Geuns RJ, et al. Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries. EuroIntervention. 2016;12(6):734\u20139.","journal-title":"EuroIntervention"},{"issue":"8","key":"1280_CR24","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/eurheartj\/ehu373","volume":"36","author":"L Raber","year":"2015","unstructured":"Raber L, Taniwaki M, Zaugg S, et al. Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. Eur Heart J. 2015;36(8):490\u2013500.","journal-title":"Eur Heart J"},{"key":"1280_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12916-015-0459-4","volume":"13","author":"M Banach","year":"2015","unstructured":"Banach M, Serban C, Sahebkar A, et al. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. BMC Med. 2015;13:229.","journal-title":"BMC Med"},{"key":"1280_CR26","doi-asserted-by":"crossref","unstructured":"Underhill HR, Yuan C, Zhao XQ et al., Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155(3):584 e581-588.","DOI":"10.1016\/j.ahj.2007.11.018"},{"issue":"4","key":"1280_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.amjcard.2014.05.035","volume":"114","author":"Y Kataoka","year":"2014","unstructured":"Kataoka Y, Puri R, Hammadah M, et al. Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol. 2014;114(4):549\u201354.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1280_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/MCA.0000000000000465","volume":"28","author":"J Dai","year":"2017","unstructured":"Dai J, Hou J, Xing L, et al. Is age an important factor for vascular response to statin therapy? A serial optical coherence tomography and intravascular ultrasound study. Coron Artery Dis. 2017;28(3):209\u201317.","journal-title":"Coron Artery Dis"},{"issue":"2","key":"1280_CR29","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jcmg.2011.11.012","volume":"5","author":"K Hattori","year":"2012","unstructured":"Hattori K, Ozaki Y, Ismail TF, et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging. 2012;5(2):169\u201377.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"1280_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.amjcard.2015.11.062","volume":"117","author":"J Hou","year":"2016","unstructured":"Hou J, Xing L, Jia H, et al. Comparison of Intensive Versus Moderate lipid-lowering therapy on fibrous Cap and Atheroma volume of coronary lipid-rich plaque using serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. Am J Cardiol. 2016;117(5):800\u20136.","journal-title":"Am J Cardiol"},{"issue":"21","key":"1280_CR31","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.jacc.2014.08.045","volume":"64","author":"K Komukai","year":"2014","unstructured":"Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol. 2014;64(21):2207\u201317.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1280_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2014.02.025","volume":"234","author":"R Nishio","year":"2014","unstructured":"Nishio R, Shinke T, Otake H, et al. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis. 2014;234(1):114\u20139.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1280_CR33","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.atherosclerosis.2008.05.014","volume":"202","author":"S Takarada","year":"2009","unstructured":"Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2009;202(2):491\u20137.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1280_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","volume":"352","author":"SE Nissen","year":"2005","unstructured":"Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"1280_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352(1):20\u20138.","journal-title":"N Engl J Med"},{"key":"1280_CR36","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624.","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"1280_CR37","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389.","journal-title":"Eur J Prev Cardiol"},{"issue":"8","key":"1280_CR38","doi-asserted-by":"publisher","first-page":"e185554","DOI":"10.1001\/jamanetworkopen.2018.5554","volume":"1","author":"K Khunti","year":"2018","unstructured":"Khunti K, Danese MD, Kutikova L, et al. Association of a combined measure of Adherence and Treatment Intensity with Cardiovascular outcomes in patients with atherosclerosis or other Cardiovascular risk factors treated with statins and\/or ezetimibe. JAMA Netw Open. 2018;1(8):e185554.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1280_CR39","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/bcp.12339","volume":"78","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol. 2014;78(4):684\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1280_CR40","first-page":"685","volume":"22","author":"I Lin","year":"2016","unstructured":"Lin I, Sung J, Sanchez RJ, et al. Patterns of statin use in a Real-World Population of patients at High Cardiovascular Risk. J Manag Care Spec Pharm. 2016;22(6):685\u201398.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1280_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2015.49807","volume":"11","author":"M Banach","year":"2015","unstructured":"Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid Expert Panel. Archives Med Science: AMS. 2015;11(1):1\u201323.","journal-title":"Archives Med Science: AMS"},{"issue":"5","key":"1280_CR42","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","volume":"12","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2024","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Electronic address cnoau, cholesterol treatment trialists C: effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306\u201319.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"1280_CR43","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1016\/j.jacc.2010.01.050","volume":"55","author":"O Bayturan","year":"2010","unstructured":"Bayturan O, Kapadia S, Nicholls SJ, et al. Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010;55(24):2736\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"1280_CR44","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","volume":"46","author":"P Libby","year":"2005","unstructured":"Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46(7):1225\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1280_CR45","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","volume":"201","author":"G Savarese","year":"2015","unstructured":"Savarese G, De Ferrari GM, Rosano GM, Perrone-Filardi P. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015;201:247\u201352.","journal-title":"Int J Cardiol"},{"issue":"5","key":"1280_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jacc.2015.05.065","volume":"66","author":"K Tsujita","year":"2015","unstructured":"Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering Strategy with Ezetimibe and Atorvastatin on Coronary Plaque regression in patients with percutaneous coronary intervention: the Multicenter Randomized Controlled PRECISE-IVUS Trial. J Am Coll Cardiol. 2015;66(5):495\u2013507.","journal-title":"J Am Coll Cardiol"},{"issue":"9784","key":"1280_CR47","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"25","key":"1280_CR48","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after Acute Coronary syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"8","key":"1280_CR49","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/imj.13451","volume":"47","author":"DJ Scherer","year":"2017","unstructured":"Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Intern Med J. 2017;47(8):856\u201365.","journal-title":"Intern Med J"},{"key":"1280_CR50","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144\u201353.","journal-title":"N Engl J Med"},{"issue":"18","key":"1280_CR51","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870\u201382.","journal-title":"JAMA"},{"issue":"19","key":"1280_CR52","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809\u201319.","journal-title":"N Engl J Med"},{"issue":"9965","key":"1280_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341\u201350.","journal-title":"Lancet"},{"issue":"6","key":"1280_CR54","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jacl.2017.09.003","volume":"11","author":"GK Hovingh","year":"2017","unstructured":"Hovingh GK, Raal FJ, Dent R, et al. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1448\u201357.","journal-title":"J Clin Lipidol"},{"issue":"48","key":"1280_CR55","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","volume":"37","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP, et al. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J. 2016;37(48):3588\u201395.","journal-title":"Eur Heart J"},{"issue":"10","key":"1280_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s11883-024-01230-6","volume":"26","author":"L Barbieri","year":"2024","unstructured":"Barbieri L, Tumminello G, Fichtner I, et al. PCSK9 and coronary artery plaque-new opportunity or Red Herring? Curr Atheroscler Rep. 2024;26(10):589\u2013602.","journal-title":"Curr Atheroscler Rep"},{"issue":"22","key":"1280_CR57","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in statin-treated patients: the GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"key":"1280_CR58","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of Evolocumab on Coronary Plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging; 2022.","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"1280_CR59","doi-asserted-by":"crossref","unstructured":"Raber L, Ueki Y, Otsuka T et al., Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA 2022.","DOI":"10.1001\/jama.2022.11836"},{"key":"1280_CR60","unstructured":"https:\/\/.health.mountsinai.org\/blog\/yellow-iii-trial-finds-that-lipid-lowering-with-a-pcsk9-inhibitor-could-benefit-patients-on-statin-therapy\/[ https:\/\/health.mountsinai.org\/blog\/yellow-iii-trial-finds-that-lipid-lowering-with-a-pcsk9-inhibitor-could-benefit-patients-on-statin-therapy\/]"},{"issue":"18","key":"1280_CR61","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical outcomes in patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"12","key":"1280_CR62","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1001\/jamacardio.2017.3944","volume":"2","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Keech A, Murphy SA, et al. Clinical efficacy and safety of Evolocumab in High-Risk patients receiving a statin: secondary analysis of patients with low LDL cholesterol levels and in those already receiving a maximal-potency statin in a Randomized Clinical Trial. JAMA Cardiol. 2017;2(12):1385\u201391.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"1280_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a Randomized Trial of Evolocumab. N Engl J Med. 2017;377(7):633\u201343.","journal-title":"N Engl J Med"},{"key":"1280_CR64","doi-asserted-by":"crossref","unstructured":"Sabatine MS, De Ferrari GM, Giugliano RP et al. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: analysis from FOURIER. Circulation 2018, 138(8):756\u201366.","DOI":"10.1161\/CIRCULATIONAHA.118.034309"},{"issue":"12","key":"1280_CR65","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"1280_CR66","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic Cardiovascular Disease. Circulation. 2022;146(15):1109\u201319.","journal-title":"Circulation"},{"issue":"22","key":"1280_CR67","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"16","key":"1280_CR68","first-page":"1408","volume":"44","author":"GG Schwartz","year":"2023","unstructured":"Schwartz GG, Szarek M, Bhatt DL, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. Eur Heart J. 2023;44(16):1408\u201317.","journal-title":"Eur Heart J"},{"issue":"2","key":"1280_CR69","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk after Acute Coronary Syndrome. J Am Coll Cardiol. 2020;75(2):133\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"1280_CR70","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520\u201330.","journal-title":"N Engl J Med"},{"key":"1280_CR71","doi-asserted-by":"crossref","unstructured":"Ray KK, Landmesser U, Leiter LA et al. Inclisiran in patients at High Cardiovascular risk with elevated LDL cholesterol. N Engl J Med 2017.","DOI":"10.1056\/NEJMoa1615758"},{"issue":"16","key":"1280_CR72","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"48","key":"1280_CR73","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357.","journal-title":"Eur Heart J"},{"key":"1280_CR74","doi-asserted-by":"crossref","unstructured":"Ray KK, Troquay RP, Visseren FL, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL-C (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lanc Diab Endo; 2022.","DOI":"10.2139\/ssrn.4252675"},{"issue":"20","key":"1280_CR75","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL Cholesterol Levels in patients with Acute Coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"1280_CR76","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.jacc.2024.03.382","volume":"83","author":"MJ Koren","year":"2024","unstructured":"Koren MJ, Rodriguez F, East C, et al. An Inclisiran First Strategy vs Usual Care in patients with atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2024;83(20):1939\u201352.","journal-title":"J Am Coll Cardiol"},{"issue":"40","key":"1280_CR77","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","volume":"44","author":"F Raal","year":"2023","unstructured":"Raal F, Fourie N, Scott R, et al. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272\u201380.","journal-title":"Eur Heart J"},{"issue":"16","key":"1280_CR78","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","volume":"81","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Banka P, Mendez G, et al. Phase 2b Randomized Trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553\u201364.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"1280_CR79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","volume":"18","author":"O Bilen","year":"2016","unstructured":"Bilen O, Ballantyne CM. Bempedoic Acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016;18(10):61.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"1280_CR80","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and Cardiovascular Disease. N Engl J Med. 2019;380(11):1033\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"1280_CR81","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1194\/jlr.M030528","volume":"54","author":"SL Pinkosky","year":"2013","unstructured":"Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1):134\u201351.","journal-title":"J Lipid Res"},{"issue":"7","key":"1280_CR82","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","volume":"45","author":"CT Cramer","year":"2004","unstructured":"Cramer CT, Goetz B, Hopson KL, et al. Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome. J Lipid Res. 2004;45(7):1289\u2013301.","journal-title":"J Lipid Res"},{"issue":"13","key":"1280_CR83","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jacc.2013.05.050","volume":"62","author":"CM Ballantyne","year":"2013","unstructured":"Ballantyne CM, Davidson MH, Macdougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13):1154\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1280_CR84","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1161\/ATVBAHA.113.302677","volume":"34","author":"MJ Gutierrez","year":"2014","unstructured":"Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3):676\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1280_CR85","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","volume":"9","author":"PD Thompson","year":"2015","unstructured":"Thompson PD, Rubino J, Janik MJ, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3):295\u2013304.","journal-title":"J Clin Lipidol"},{"issue":"12","key":"1280_CR86","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1016\/j.amjcard.2016.03.043","volume":"117","author":"CM Ballantyne","year":"2016","unstructured":"Ballantyne CM, McKenney JM, MacDougall DE, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117(12):1928\u201333.","journal-title":"Am J Cardiol"},{"key":"1280_CR87","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","volume":"277","author":"CM Ballantyne","year":"2018","unstructured":"Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018;277:195\u2013203.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1280_CR88","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"KK Ray","year":"2019","unstructured":"Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11):1022\u201332.","journal-title":"N Engl J Med"},{"issue":"18","key":"1280_CR89","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"AC Goldberg","year":"2019","unstructured":"Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of Bempedoic Acid vs Placebo added to maximally tolerated statins on Low-Density Lipoprotein Cholesterol in patients at High Risk for Cardiovascular Disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322(18):1780\u20138.","journal-title":"JAMA"},{"issue":"7","key":"1280_CR90","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, et al. Efficacy and safety of Bempedoic Acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1280_CR91","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1177\/2047487319864671","volume":"27","author":"CM Ballantyne","year":"2020","unstructured":"Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593\u2013603.","journal-title":"Eur J Prev Cardiol"},{"key":"1280_CR92","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.atherosclerosis.2020.12.023","volume":"320","author":"J Rubino","year":"2021","unstructured":"Rubino J, MacDougall DE, Sterling LR, Hanselman JC, Nicholls SJ. Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: a randomized clinical trial. Atherosclerosis. 2021;320:122\u20138.","journal-title":"Atherosclerosis"},{"issue":"15","key":"1280_CR93","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"key":"1280_CR94","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2020.10.060","volume":"235","author":"S Nicholls","year":"2021","unstructured":"Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104\u201312.","journal-title":"Am Heart J"},{"issue":"22","key":"1280_CR95","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1161\/CIRCULATIONAHA.123.067691","volume":"149","author":"L Cho","year":"2024","unstructured":"Cho L, Plutzky J, Brennan D, et al. Impact of Bempedoic Acid on Cardiovascular outcomes by Sex. Circulation. 2024;149(22):1775\u20137.","journal-title":"Circulation"},{"issue":"2","key":"1280_CR96","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","volume":"84","author":"AM Lincoff","year":"2024","unstructured":"Lincoff AM, Ray KK, Sasiela WJ, et al. Comparative Cardiovascular benefits of Bempedoic Acid and Statin drugs. J Am Coll Cardiol. 2024;84(2):152\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1280_CR97","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jama.2023.9696","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Menon V, Nicholls SJ, et al. Bempedoic Acid for Primary Prevention of Cardiovascular events in statin-intolerant patients. JAMA. 2023;330(2):131\u201340.","journal-title":"JAMA"},{"issue":"1","key":"1280_CR98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/MOL.0000000000000473","volume":"29","author":"LF Reeskamp","year":"2018","unstructured":"Reeskamp LF, Meessen ECE, Groen AK. Transintestinal cholesterol excretion in humans. Curr Opin Lipidol. 2018;29(1):10\u20137.","journal-title":"Curr Opin Lipidol"},{"issue":"10","key":"1280_CR99","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1161\/ATVBAHA.119.312952","volume":"39","author":"J Li","year":"2019","unstructured":"Li J, Pijut SS, Wang Y, et al. Simultaneous determination of biliary and intestinal cholesterol secretion reveals that CETP (Cholesteryl Ester Transfer Protein) alters Elimination Route in mice. Arterioscler Thromb Vasc Biol. 2019;39(10):1986\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"14","key":"1280_CR100","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2022","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl Ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2022;118(14):2919\u201331.","journal-title":"Cardiovasc Res"},{"issue":"21","key":"1280_CR101","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"1280_CR102","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"1280_CR103","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ahj.2015.09.007","volume":"170","author":"SJ Nicholls","year":"2015","unstructured":"Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. Am Heart J. 2015;170(6):1061\u20139.","journal-title":"Am Heart J"},{"issue":"13","key":"1280_CR104","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"L Bowman","year":"2017","unstructured":"Hps Timi Reveal Collaborative Group, Bowman L, Hopewell JC, et al. Effects of Anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327.","journal-title":"N Engl J Med"},{"issue":"14","key":"1280_CR105","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1093\/eurheartj\/ehab863","volume":"43","author":"HTRC Group","year":"2022","unstructured":"Group HTRC, Writing C, Sammons E, et al. Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease. Eur Heart J. 2022;43(14):1416\u201324.","journal-title":"Eur Heart J"},{"issue":"5","key":"1280_CR106","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1172\/JCI117537","volume":"94","author":"A Inazu","year":"1994","unstructured":"Inazu A, Jiang XC, Haraki T, et al. Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol. J Clin Invest. 1994;94(5):1872\u201382.","journal-title":"J Clin Invest"},{"issue":"10","key":"1280_CR107","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"BA Ference","year":"2017","unstructured":"Ference BA, Kastelein JJP, Ginsberg HN, et al. Association of Genetic Variants Related to CETP inhibitors and statins with lipoprotein levels and Cardiovascular Risk. JAMA. 2017;318(10):947\u201356.","journal-title":"JAMA"},{"issue":"11","key":"1280_CR108","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrcardio.2017.156","volume":"14","author":"MV Holmes","year":"2017","unstructured":"Holmes MV, Smith GD. Dyslipidaemia: revealing the effect of CETP inhibition in cardiovascular disease. Nat Rev Cardiol. 2017;14(11):635\u20136.","journal-title":"Nat Rev Cardiol"},{"key":"1280_CR109","doi-asserted-by":"crossref","unstructured":"Nelson AJ, Sniderman AD, Ditmarsch M et al. Cholesteryl Ester Transfer Protein Inhibition reduces major adverse Cardiovascular events by lowering apolipoprotein B levels. Int J Mol Sci 2022, 23(16).","DOI":"10.3390\/ijms23169417"},{"issue":"9992","key":"1280_CR110","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJ, van Deventer SJ, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452\u201360.","journal-title":"Lancet"},{"issue":"8","key":"1280_CR111","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"1280_CR112","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJ, et al. Obicetrapib plus Ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503.","journal-title":"J Clin Lipidol"},{"key":"1280_CR113","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ahj.2024.05.002","volume":"274","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024;274:32\u201345.","journal-title":"Am Heart J"},{"issue":"9719","key":"1280_CR114","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9719):998\u20131006.","journal-title":"Lancet"},{"issue":"7","key":"1280_CR115","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","volume":"79","author":"F Fogacci","year":"2019","unstructured":"Fogacci F, Ferri N, Toth PP, Ruscica M, Corsini A, Cicero AFG. Efficacy and safety of Mipomersen: a systematic review and Meta-analysis of Randomized clinical trials. Drugs. 2019;79(7):751\u201366.","journal-title":"Drugs"},{"issue":"6","key":"1280_CR116","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jacl.2020.08.006","volume":"14","author":"JA Underberg","year":"2020","unstructured":"Underberg JA, Cannon CP, Larrey D, Makris L, Blom D, Phillips H. Long-term safety and efficacy of lomitapide in patients with homozygous familial hypercholesterolemia: five-year data from the Lomitapide Observational Worldwide evaluation Registry (LOWER). J Clin Lipidol. 2020;14(6):807\u201317.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"1280_CR117","first-page":"72","volume":"18","author":"GB Lim","year":"2021","unstructured":"Lim GB. ANGPTL3 inhibition for hypercholesterolaemia. Nat Reviews Cardiol. 2021;18(2):72.","journal-title":"Nat Reviews Cardiol"},{"issue":"3","key":"1280_CR118","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and Cardiovascular Disease. N Engl J Med. 2017;377(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"1280_CR119","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320.","journal-title":"N Engl J Med"},{"issue":"11","key":"1280_CR120","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11883-023-01156-5","volume":"25","author":"S Carugo","year":"2023","unstructured":"Carugo S, Sirtori CR, Gelpi G, Corsini A, Tokgozoglu L, Ruscica M. Updates in small interfering RNA for the treatment of Dyslipidemias. Curr Atheroscler Rep. 2023;25(11):805\u201317.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"1280_CR121","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa2404147","volume":"391","author":"RS Rosenson","year":"2024","unstructured":"Rosenson RS, Gaudet D, Hegele RA, et al. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia. N Engl J Med. 2024;391(10):913\u201325.","journal-title":"N Engl J Med"},{"issue":"4","key":"1280_CR122","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11883-021-00911-w","volume":"23","author":"M Kayikcioglu","year":"2021","unstructured":"Kayikcioglu M. LDL apheresis and lp (a) apheresis: a clinician\u2019s perspective. Curr Atheroscler Rep. 2021;23(4):15.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"1280_CR123","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41569-023-00972-1","volume":"21","author":"AJ Nelson","year":"2024","unstructured":"Nelson AJ, Pagidipati NJ, Bosworth HB. Improving medication adherence in cardiovascular disease. Nat Reviews Cardiol. 2024;21(6):417\u201329.","journal-title":"Nat Reviews Cardiol"},{"issue":"1","key":"1280_CR124","doi-asserted-by":"publisher","first-page":"100749","DOI":"10.1016\/j.jacadv.2023.100749","volume":"3","author":"CM Ballantyne","year":"2024","unstructured":"Ballantyne CM, Agarwala A. Reinstating LDL-C measurement as a Quality Metric: this is the way. JACC Adv. 2024;3(1):100749.","journal-title":"JACC Adv"},{"issue":"10349","key":"1280_CR125","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","volume":"400","author":"BK Kim","year":"2022","unstructured":"Kim BK, Hong SJ, Lee YJ, et al. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Lancet. 2022;400(10349):380\u201390.","journal-title":"Lancet"},{"issue":"7859","key":"1280_CR126","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01280-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01280-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T21:38:25Z","timestamp":1739655505000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01280-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":126,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01280-4","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"7 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"SJN has received research support from AstraZeneca, Amgen, Anthera, CSL Behring, Cerenis, Eli Lilly, Esperion, Resverlogix, Novartis, InfraReDx and Sanofi-Regeneron and is a consultant for Amgen, Akcea, AstraZeneca, Boehringer Ingelheim, CSL Behring, Daiichi Sankyo, Eli Lilly, Esperion, Kowa, Merck, Takeda, Pfizer, Sanofi-Regeneron, Novo Nordisk, CSL Sequiris and Vaxxinity. AJN has received research support from AstraZeneca, Amgen, Eli Lilly, Novartis and is a consultant for Amgen, AstraZeneca, Boehringer Ingelheim, CSL Sequiris, Eli Lilly, GSK, Sanofi Pasteur and Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"32"}}